Citation 102827

GORDON,M: DEEKS,S: DE MARZO,C: GOODGAME,J: GURALNIK,M: LANG,W: MIMURA,T: PEARCE,D: KANEKO,Y:. (1997). CURDLAN SULFATE (CRDS) IN A 21-DAY INTRAVENOUS TOLERANCE STUDY IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND CYTOMEGALOVIRUS (CMV) INFECTED PATIENTS: INDICATION OF ANTI-CMV ACTIVITY WITH LOW TOXICITY.. 28(1/2)

Citation Details

TitleCURDLAN SULFATE (CRDS) IN A 21-DAY INTRAVENOUS TOLERANCE STUDY IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND CYTOMEGALOVIRUS (CMV) INFECTED PATIENTS: INDICATION OF ANTI-CMV ACTIVITY WITH LOW TOXICITY.
AuthorsGORDON,M: DEEKS,S: DE MARZO,C: GOODGAME,J: GURALNIK,M: LANG,W: MIMURA,T: PEARCE,D: KANEKO,Y:
Year1997
Volume28
Issue1/2

Summary

Year: 1997

Journal: Unknown

Organisms and Their Experiments (1)

Unknown organism

Experiment #Pharmacology TypeWorktypesCompoundResults
1
ANTIVIRAL ACTIVITY
PHARMACOLOGY OF COMPOUND - IN HUMANSANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)
CURDLAN SULFATE
ACTIVE
2
LYMPHOCYTE PROLIFERATION STIMULATION
PHARMACOLOGY OF COMPOUND - IN HUMANSANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)
CURDLAN SULFATE
ACTIVE
3
LYMPHOCYTE PROLIFERATION STIMULATION
PHARMACOLOGY OF COMPOUND - IN HUMANS
CURDLAN SULFATE
ACTIVE
4
ANTIVIRAL ACTIVITY
PHARMACOLOGY OF COMPOUND - IN HUMANSANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)
CURDLAN SULFATE
WEAK ACTIVITY
5
PLATELET AGGREGATION INHIBITION
PHARMACOLOGY OF COMPOUND - IN HUMANS
CURDLAN SULFATE
INACTIVE
Show SPARQL Queries (1)